# Natco Pharma

> Natco Pharma is a VC fund in Hyderabad backing Health Care and Biotechnology. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hyderabad, India
- Total investments: 6
- Last investment: Sep 2024
- Lead investor: 50%
- Last updated: Aug 2026
- X (Twitter): https://twitter.com/natcopharmaltd
- Website: https://www.natcopharma.co.in/
- Facebook: https://www.facebook.com/natcopharma/

Natco Pharma is a manufacture and market affordable medicines that comply with global standards and to achieve market leadership in domestic as well as international markets.

## Contacts

5 contacts available for Natco Pharma. Shizune tracks 2 team members at Natco Pharma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/natco-pharma?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 50% |
| Biotechnology | 2 | 33% |
| Fitness | 1 | 17% |
| Medical | 1 | 17% |
| Genetics | 1 | 17% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 33% |
| Series A | 1 | 17% |
| Series D | 1 | 17% |
| Funding Round | 1 | 17% |
| Corporate Round | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 4 | 67% |
| United States | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Rajeev Nannapaneni | Vice Chairman and CEO | 1 | https://shizune.co/investors/profile/rajeev-nannapaneni |
| Appa Rao S V V N | Chief Financial Officer | 0 | https://shizune.co/investors/profile/appa-rao-s-v-v-n |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EGenesis | EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $191M | Series D | Sep 04, 2024 |  |
| Cellogen Therapeutics | Cellogen Therapeutics is a biotech company that is currently working on developing revolutionary cell therapy-based solutions. It treats a variety of hematological malignancies, solid tumors, and hemoglobinopathies using modern cellular engineering tools and gene therapy. | $1.8M | Corporate Round | Jan 17, 2024 |  |
| Pee Safe | Pee Safe was started in 2013, launching the first of its kind toilet seat sanitizer. Since 2017, the company has expanded into several personal hygiene categories including feminine hygiene (pads, tampons, cups, etc), men's intimate hygiene, hand hygiene (Palm Safe), face mask and mist (Pollution Safe), while being one of the leaders in a fewsub-categories. | $3M | Series B | Sep 11, 2023 |  |
| Eyestem | Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treatincurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety. | $6.4M | Series A | Aug 08, 2022 |  |
| CION Cancer Clinics | CION Cancer Clinics operates a distributed network of day-care cancer treatment centers. | $1.5M |  | Mar 24, 2021 |  |
| Eyestem | Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treatincurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety. | $10M | Series B |  |  |

6 of 6 investments shown.

## Co-investors
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 2 deals together
- [M Venture Partners (MVP)](https://shizune.co/investors/profile/3t-venture-capital-partners) — VC Fund, 1 deal together
- [Alkemi Venture Partners](https://shizune.co/investors/profile/alkemi-venture-partners) — VC Fund, 1 deal together
- [Alkem Laboratories](https://shizune.co/investors/profile/alkem-laboratories) — VC Fund, 1 deal together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Natco Pharma invest in?

Natco Pharma invests primarily in Health Care, Biotechnology and Fitness startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Natco Pharma?

Public channels for Natco Pharma include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Natco Pharma?

The team at Natco Pharma includes Rajeev Nannapaneni (Vice Chairman and CEO) and Appa Rao S V V N (Chief Financial Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co